Renovaro (RENB) Competitors $0.20 0.00 (-0.95%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.21 +0.01 (+4.18%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RENB vs. CYBN, MEIP, KYTX, CTOR, GLSI, MIST, MOLN, ELDN, CLYM, and THTXShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Cybin (CYBN), MEI Pharma (MEIP), Kyverna Therapeutics (KYTX), Citius Oncology (CTOR), Greenwich LifeSciences (GLSI), Milestone Pharmaceuticals (MIST), Molecular Partners (MOLN), Eledon Pharmaceuticals (ELDN), Climb Bio (CLYM), and Theratechnologies (THTX). These companies are all part of the "pharmaceutical products" industry. Renovaro vs. Its Competitors Cybin MEI Pharma Kyverna Therapeutics Citius Oncology Greenwich LifeSciences Milestone Pharmaceuticals Molecular Partners Eledon Pharmaceuticals Climb Bio Theratechnologies Cybin (NYSE:CYBN) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk. Do analysts prefer CYBN or RENB? Cybin presently has a consensus target price of $85.00, indicating a potential upside of 1,295.73%. Given Cybin's stronger consensus rating and higher probable upside, research analysts plainly believe Cybin is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, CYBN or RENB? Cybin has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Do institutionals and insiders believe in CYBN or RENB? 17.9% of Cybin shares are owned by institutional investors. Comparatively, 71.4% of Renovaro shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 0.5% of Renovaro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor CYBN or RENB? In the previous week, Cybin had 5 more articles in the media than Renovaro. MarketBeat recorded 7 mentions for Cybin and 2 mentions for Renovaro. Renovaro's average media sentiment score of 0.43 beat Cybin's score of 0.14 indicating that Renovaro is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Renovaro 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation and earnings, CYBN or RENB? Cybin is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$4.60-1.32RenovaroN/AN/A-$88.43M-$0.77-0.26 Is CYBN or RENB more profitable? Cybin's return on equity of -37.58% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Renovaro N/A -60.38%-47.04% SummaryCybin beats Renovaro on 10 of the 14 factors compared between the two stocks. Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.53M$3.20B$5.87B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-0.2621.1774.5225.93Price / SalesN/A476.06548.33126.97Price / CashN/A46.6837.5660.44Price / Book0.229.6112.166.29Net Income-$88.43M-$53.29M$3.28B$270.77M7 Day Performance-3.78%0.28%0.87%3.88%1 Month Performance-17.72%5.73%4.96%4.88%1 Year Performance-69.66%10.52%60.74%26.01% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro0.8704 of 5 stars$0.20-0.9%N/A-68.0%$34.53MN/A-0.2620CYBNCybin2.668 of 5 stars$6.73-10.1%$85.00+1,163.9%N/A$159.12MN/A-1.5450High Trading VolumeMEIPMEI Pharma1.308 of 5 stars$4.84-0.4%N/A+4.2%$158.95M$65.30M-1.02100Upcoming EarningsGap UpKYTXKyverna Therapeutics3.3317 of 5 stars$3.66-1.3%$16.60+353.6%-43.9%$158.30M$7.03M-0.9996Gap UpCTORCitius Oncology1.8041 of 5 stars$2.01-7.4%$3.00+49.3%+16.5%$157.52MN/A0.00N/AGLSIGreenwich LifeSciences1.5317 of 5 stars$11.49+0.0%$42.00+265.7%-21.2%$156.53MN/A-8.443Positive NewsMISTMilestone Pharmaceuticals2.4683 of 5 stars$1.84-0.3%$5.00+172.5%+33.3%$155.96M$1M-2.1830News CoveragePositive NewsAnalyst ForecastMOLNMolecular Partners1.999 of 5 stars$3.81+1.6%$12.00+215.0%-33.4%$153.85M$5.65M-1.83180Gap UpELDNEledon Pharmaceuticals3.0099 of 5 stars$2.56-1.2%$10.00+290.8%-4.0%$152.99MN/A-2.1810News CoveragePositive NewsShort Interest ↓CLYMClimb Bio3.7193 of 5 stars$2.21-0.9%$9.00+307.2%N/A$149.75MN/A-3.169Positive NewsGap UpTHTXTheratechnologiesN/A$3.25+0.2%N/A+166.1%$149.21M$85.87M-17.08140News CoverageShort Interest ↓ Related Companies and Tools Related Companies Cybin Alternatives MEI Pharma Alternatives Kyverna Therapeutics Alternatives Citius Oncology Alternatives Greenwich LifeSciences Alternatives Milestone Pharmaceuticals Alternatives Molecular Partners Alternatives Eledon Pharmaceuticals Alternatives Climb Bio Alternatives Theratechnologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RENB) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RENB Stock Alerts